Generics - Biotechnology, Novartis

Filter

Current filters:

BiotechnologyNovartis

Popular Filters

US pulmonologists view refractory asthma patient treatment with biosimilar Xolair by end-2018

10-04-2013

US pulmonologists surveyed by health care advisory firm Decision Resources estimate that only 19% percent…

BiotechnologyBoehringer IngelheimGenentechGenericsMarkets & MarketingNorth AmericaNovartisPfizerRespiratory and PulmonarySpirivaXolair

"Sandoz will be the leading biosimilars company in 2012," says Visiongain

04-10-2012

Sandoz, the generics unit of Swiss drug major Novartis (NVN: VX), will retain its position as the global…

BiotechnologyDr Reddy's LaboratoriesGenericsGlobalHospiraMarkets & MarketingNovartisSandoz

FDA approves pediatric Afinitor from Novartis and Teva's tbo-filgrastim

30-08-2012

The US Food and Drug Administration yesterday approved Swiss drug major Novartis' (NOVN: VX) Afinitor…

AfinitorBiotechnologyGenericsNorth AmericaNovartisOncologyPharmaceuticalRegulationSicor Biotechtbo-filgrastimTeva Pharmaceutical Industries

Biosimilars can save eight EU countries up to 33 billion euros on health care by 2020

16-05-2012

By 2020, eight countries in the European Union could save a cumulative total of between 11.8 billion…

BiotechnologyEuropeGenericsHealthcareNovartisPricingSandoz

EMA starts review of Gilenya; guidance on biosimilar interferon beta

23-01-2012

The European Medicines Agency has begun a review of the benefits and risks of Swiss drug major Novartis’…

BiotechnologyEuropeGenericsGilenyainterferon betaNeurologicalNovartisPharmaceuticalRegulation

Sandoz initiates two more Phase III biosimilar trials

20-01-2012

Sandoz, the generics unit of Swiss drug major Novartis (NOVN: VX), says that it has initiated two milestone…

AmgenBiotechnologyFilgrastimGenericsNovartisOncologypegfilgrastimResearchSandozZarzio

Back to top